| abstract |
A method of prevention of age-related macular degeneration (AMD) is provided where a sample is taken from an individual and the presence of a polymorphism associated with a dehydrogenase, oxygenase, acyltransferase, dismutase or a macular or retinal pigment, or an SNP as shown in Table 1 of the specification, is detected. The individual can then be provided with a substance that can prevent or treat AMD, or can mitigate or alleviate symptoms of AMD. The substance is a medication comprising lutein and/or zeaxanthin and/or certain antioxidants (or a mixture thereof) is tailored to that individual. |